NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$18.48 USD
-0.64 (-3.32%)
Updated Jul 18, 2024 04:00 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
NovoCure Limited [NVCR]
Reports for Purchase
Showing records 1 - 20 ( 216 total )
Company: NovoCure Limited
Industry: Medical Services
Key Takeaways for ASCO 2024; Roundup for Covered Companies (Pt. 2)
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
METIS Presentation at ASCO Provides More Granular Detail on Efficacy and Safety
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
1Q24 Recap: Day-100 FDA Meeting Completed For NSCLC; Optune Fundamentals Improving
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
METIS Passes the Litmus Test, But the Acid Test Comes Later
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
METIS Study Hits on Primary Endpoint, Though Not a Home Run, in Our View
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
INNOVATE-3 Subgroup Data Indicate Efficacy in Earlier Stage Ovarian Cancer Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
INNOVATE-3 Innovating in PLD-naive Ovarian Cancer
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
4Q23 Recap: Several Large Catalysts on Track For 2024 Though Some Uncertainties Persist
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Preliminary 4Q23 Optune Revenues Indicate Improving Growth Dynamics; 2L NSCLC PMA Submitted
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: NovoCure Limited
Industry: Medical Services
NVCR Looking for Lung to Breathe Life into Revenues
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D